|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.
|
30745584 |
2019 |
|
Malignant neoplasm of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Detection of a single ERBB2-amplified DCC was the most important risk factor for death from esophageal cancer (relative risk = 4.22; 95% CI = 1.91-9.32; p < 0.001).
|
29044505 |
2018 |
|
Malignant neoplasm of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described.
|
29223420 |
2018 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
The key to effective treatment of HER2 amplified GOC lies in understanding these mechanisms and tailoring HER2 inhibition for GOC patients in order to improve clinical outcomes.
|
30079142 |
2018 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Trastuzumab combined with chemotherapy is standard of care for HER2 positive advanced gastro-esophageal cancers.
|
28600510 |
2017 |
|
Malignant neoplasm of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of 545 patients accrued to the trial (gastric, 87.3%; GEJ, 8.3% and esophageal cancer, 4.4%), 487 patients (89%) were centrally confirmed as having HER2-amplified disease.
|
27811012 |
2017 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
With standardized HER2 testing in gastro-esophageal cancer, the ongoing trials are testing newer agents and combinations including combination of anti-HER2 antibodies with immunotherapy.
|
28387541 |
2017 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
|
28823752 |
2017 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with advanced or metastatic oesophageal cancer are treated with palliative chemotherapy; those who are human epidermal growth factor receptor 2 (HER2)-positive may also benefit from trastuzumab treatment.
|
28748917 |
2017 |
|
Malignant neoplasm of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HER2 expression was analysed by immunohistochemistry (IHC) and silver in situ hybridization (SISH) in 152 archival oesophageal cancer specimens.
|
26422587 |
2016 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.
|
27741011 |
2016 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
This receptor tyrosine kinase is upregulated in 10-20% of esophageal squamous cell carcinoma (ESCC) tissues, and amplification of ERBB2 has been correlated with poor prognosis in esophageal cancer.
|
27203740 |
2016 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, concomitant blockage of the ErbB2-PI3K pathway and the Hedgehog downstream mediator Gli-1 may provide a new therapeutic strategy for esophageal cancer.
|
25435423 |
2015 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
|
25694417 |
2015 |
|
Malignant neoplasm of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Targeted ERBB2/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively.
|
25480824 |
2015 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer.
|
25576545 |
2015 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Automation of HER2 FISH analysis in oesophageal cancer has not been performed before.
|
24043715 |
2014 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).
|
24206575 |
2013 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 positivity does not seem to predispose to brain colonization in gastro-esophageal cancer.
|
23482783 |
2013 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the antitumor effects of lapatinib, a dual tyrosine kinase inhibitor which simultaneously inhibits EGFR and HER2, 5-fluorouracil (5-Fu) alone and in combination on esophageal cancer cells.
|
22293713 |
2012 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
|
22767218 |
2012 |
|
Malignant neoplasm of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Discovery of the over-expression of Her-2/neu or the amplification of its regulatory gene in stomach and esophageal cancer has resulted in targeted treatment directed at this protein.
|
21783379 |
2012 |
|
Malignant neoplasm of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The copy number variation of erbB2 gene from plasma can be used as prognostic marker for early detection of patients at risk of worse clinical outcome in esophageal cancer.
|
21481261 |
2011 |
|
Malignant neoplasm of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
|
21207425 |
2011 |
|
Malignant neoplasm of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
True HER2 gene amplification was detected in 14 esophageal cancer specimens (16%), and 92% of those with high-level HER2 amplification showed positive HER2 protein overexpression.
|
21267790 |
2011 |